

PHARMACOLOGY

RR-8.0

Contents

General Pharmacology : Part 1	1
General Pharmacology : Part 2	7
Drugs Acting on Autonomic Nervous System	14
Drugs acting on Cardiovascular System : Part 1	20
Drugs acting on Cardiovascular System : Part 2	24
Drugs Acting on Kidney	30
Drugs Acting on Central Nervous System	32
Antibiotics : Part 1	42
Antibiotics : Part 2	48
Drugs Acting on Endocrine System	54
Autacoids	61
Drugs Acting on Respiratory System, GIT and Blood	66
Anti Neoplastic agents and Immunomodulators	73

GENERAL PHARMACOLOGY : PART 1

----- Active space -----

Types of Drugs

00:07:58

Orphan drugs :

used for rare diseases → ↓ Profitability (↓ Development of drug).

Note : Orphan receptor → Receptor with unknown ligand.

Essential drugs :

meets healthcare needs of the majority of a population :

- Inexpensive.
- Non-toxic.
- Easily available.
- Efficacious.
- Safe.
- Single molecule (Not fixed dose combination).

Prescription/legend drugs : Require prescription (Under Schedule H).

Spurious drugs : Does not produce expected effect as drug component is falsified.

misbranded drugs : Incorrect or missing information on drug label.

Adulterated drug : unwanted additive in drug.

Rational Drug Use :

use of right drug for right disease & patient; at right dose, duration & route with right dispensation & monitoring ("Right price" not included).

Movement of Drug Through the Body (ADME)

00:08:00




Note : Pharmacodynamics → Drug induced change in body via receptor binding (Drug receptor effect).

Drug Absorption

00:10:10

- m/c mechanism : Passive diffusion along concentration gradient.
 (Lipid soluble; unionised drugs → pH of drug = pH of medium).
- maximum absorption of drug in GIT : Small intestine (D/t large surface area).
- Poor oral absorption : Drugs with large size (Eg : Proteins → Drugs with -tide/-ase/-mab).

----- Active space -----

Types of Tablets/Capsules :

Uses of controlled/sustained release :

- ↑ Duration of effect → ↓ no. of doses. (useful if $t_{1/2} < 4h$).
- ↓ Risk of acute toxicity : D/t lower/absent peak concentration.

Enteric coated drugs :


- HCl-resistant membrane coating used.
- Prevents drug breakdown in acidic pH of stomach.

Extent of Absorption :


- Amount of drug absorbed.
- AKA **bioavailability**.
- Formula :

$$\text{Bioavailability} = \frac{\text{AUC}_{\text{oral}}}{\text{AUC}_{\text{IV}}}$$

(AUC = Area under curve)

**Rate of Absorption :**

- Amount of drug absorbed per unit of time.
- Determined by T_{max} .



Note → **RATE** : Rate → T_{max}
AUC → Extent

ATP-binding Cassette (ABC) :

AKA : p-glycoprotein/multi-drug resistance (MDR)-1 pumps.

Physiological functions :

1. Intestine/liver : **Drug efflux** (Eg : Digoxin).
 ↓ Drug concentration in systemic circulation due to removal.
2. Blood brain barrier : Limit drug exposure to central nervous system.
 Removes drugs that cross the BBB → No central effects (Eg : Loperamide).
3. In liver : Excretion of bile acids.

----- Active space -----

Pathological function :

Cancer cells/bacteria : use the pump to remove drug. (Confers resistance → AKA MDR-1 pump).

p-GP/MDR-1 substrates		p-GP/MDR-1 inducers
<ul style="list-style-type: none"> Loperamide Methadone Nelfinavir Cyclosporine CCB (verapamil) 	<ul style="list-style-type: none"> Digoxin Erythromycin, Clarithromycin Quinidine Ranolazine Sotalolol 	Enzyme inducers like : <ul style="list-style-type: none"> Rifampicin Phenytoin Carbamazepine


Significance :

- pGP substrates competitively inhibit each other → ↑ Toxicity of either drug.
Eg :
 - Clarithromycin + Digoxin → Digoxin toxicity.
 - Quinidine → Loperamide induced CNS toxicity (Crosses BBB).
- pGP inducers cause drug failure.
Eg : Rifampicin + Digoxin → ↑ Digoxin efflux → Rx failure.
- pGP substrates can cause cholestatic jaundice :
D/t competitive inhibition of bile acid excretion. Eg : Cyclosporine.
- pGP inhibitors can be used to reverse drug resistance.
m/c used : verapamil.

Drug Distribution

00:32:17

Volume of Distribution (V_d) :



Formulae :

$$\text{Apparent } V_d (aV_d) \text{ (Liters)} = \frac{D}{C_o} = \frac{\text{Dose via IV route}}{\text{Initial PC}}$$

$$\text{Loading dose} = aV_d \times C_T \text{ (Target PC)}$$

Note : Loading dose \propto aV_d .

----- Active space -----

Significance :

Dialysis : Not effective for high V_d drugs.

Drugs with $\uparrow V_d$ (BAD DOC)	Antidote
Benzodiazepine	Flumazenil
β -blocker	Glucagon
Amphetamines	Ammonium chloride
Digoxin	Digibind
Opioids	Naloxone
Organophosphates	Atropine
Calcium channel blockers	Calcium gluconate

Plasma Protein Binding :

Proteins :

Albumin (m/c)	Alpha-1-acid glycoprotein
Binds to acidic drugs	Binds to basic drugs
<ul style="list-style-type: none"> Aspirin Anti-coagulant (warfarin) Anti-epileptics/Anti-psychotics/Anti-depressants Antibiotics (Sulfonamides) 	<ul style="list-style-type: none"> Opioids Tricyclic anti-depressants β-blockers Anti-arrhythmics (Amiodarone/Lidocaine)

Significance :

1. Liver cirrhosis :

 \downarrow Albumin production \rightarrow \downarrow Drug binding \rightarrow \uparrow Free drug \rightarrow \uparrow Toxicity.

2. Nephrotic syndrome/Chronic kidney disease :

 \uparrow Albumin excretion \rightarrow \uparrow Drug excretion \rightarrow Drug failure.3. \uparrow Alpha-1-acid glycoprotein :Seen in RA, IBD, MI \rightarrow \downarrow Free drug \rightarrow Drug failure.**Drug Metabolism**


00:45:12

Phase I vs. Phase II Reactions :

	Phase I reactions	Phase II reactions
Purpose	Drug inactivation	make drug water soluble
m/c reaction	Oxidation	Glucuronidation
m/c enzyme	CYP3A4	Glucuronyl transferase (GT)

Note :

• Nomenclature of enzymes :



- Crigler-Najjar syndrome : ↓GT → ↑Toxicity of → Irinotecan (Anti-cancer).
→ Atazanavir (Anti-HIV).

Drug - Enzyme Interaction :

	Enzyme inducers	Enzyme inhibitors
Effect	Cause drug failure	Cause drug toxicity
Examples	mnemonic : GRAB PC • Griseofulvin • Rifampicin • Alcohol (Chronic consumption) • Benzopyrene • Phenytoin, Phenobarbital, Primidone • Carbamazepine, Cigarettes	mnemonic : QUICK VEG, DISK • Quinidine • Isoniazid, Protease inhibitors • Cimetidine, Chloramphenicol, Ciprofloxacin • Ketoconazole, Itraconazole, Fluconazole • Valproate Erythromycin, Clarithromycin • Grapefruit juice • DEC, Delavirdine, Disulfiram
Important drug interactions	Rifampicin : • OCP failure • c/i in HIV with TB	• Erythromycin → Theophylline toxicity • Clarithromycin → Statin toxicity

Drugs metabolised by Plasma Esterase :

Quick action of plasma esterase → Short $t_{1/2}$ of drugs.

Examples : Plasma Esterase Can Readily metabolise Short Acting drugs.

- Procaine, cocaine.
- Esmolol.
- Clevidipine.
- Remifentanyl, Remimazolam.
- Mivacurium.
- Succinylcholine.
- Acetylcholine.

Drug Excretion

00:54:52

m/c organ : Kidney (Drug needs to be ionized & water soluble).
 → (Acidic drug → Basic media and vice versa).

Significance :

Drug toxicity :

- Acidic drugs (Aspirin, Phenobarbital) → Alkalinisation of urine with bicarbonate.
- Basic drugs (Amphetamines) → Acidification of urine with ammonium chloride.

mechanisms :

- Filtration : Only free drug excreted.
- Tubular secretion : Free + plasma protein bound drug excreted.

Calculations :

Rate of drug elimination : Amount of drug excreted per unit of time.

$$\text{Rate} = P.C. \times \text{clearance (In mg/hr)}$$

----- Active space -----

Infusion rate (IR) : Amount of drug to be administered per unit of time.

$$\text{IR : Rate of drug elimination} = \text{P.C.} \times \text{clearance}$$

Maintenance dose : Dose required to maintain steady state of drug P.C.

$$\text{MD} = \text{P.C.} \times \text{clearance} \times \text{time}$$

Half-life :

$$t_{1/2} = \frac{0.693 \times V_d}{\text{Clearance}} = \frac{0.693}{k_{\text{elimination}}}$$

Note : Infusion rate ξ maintenance dose \propto Clearance.

Order of Kinetics :

	Zero order kinetics	First order kinetics
Definition	Constant amount eliminated per hour	Constant proportion eliminated per hour
effect of \uparrow sing dose	<ul style="list-style-type: none"> $T_{1/2} \uparrow$ Clearance \downarrow P.C. : Disproportionate \uparrow 	<ul style="list-style-type: none"> $T_{1/2}$ constant Clearance constant P.C. : Proportionate \uparrow
Risk of toxicity on overdosing	Higher	Lower
Examples	<p>Zero ATP Has made Weak :</p> <ul style="list-style-type: none"> Alcohol Theophylline, Tolbutamide Phenytoin Heparin methanol Warfarin 	most drugs

GENERAL PHARMACOLOGY : PART 2

----- Active space -----

Drug $\xrightarrow{\text{Binds to}}$ Receptor $\xrightarrow{\text{Causes}}$ Effect.

Factors Affecting Pharmacodynamics :

Affinity :

- Tendency of a drug to bind to its receptor.
- marker of dose $\left[\text{Affinity} \propto \frac{1}{\text{Dose}} \right]$.

Efficacy :

- maximum clinical effect produced by a drug (most important factor).
- **marker of effect** of drug.

Potency :


- Relative dose of a drug required to produce particular effect.
- Potency $\propto \frac{1}{\text{Dose}}$.

Dose-Response Curve (DRC)

00:05:45

Graded Curve :


Response is graded.



Individual responses noted.

- Efficacy : Height of curve. $\left. \begin{array}{l} \rightarrow C > A > B. \end{array} \right\} \text{HELP}$
- Potency : Left shift. $\left. \begin{array}{l} \rightarrow A > B > C. \end{array} \right\}$
- Affinity :
Compared only if acting on the same receptor.
 - Parallel graphs = Same receptor.
 - $A > B$.

Quantal Curve :



- Response : Binary (Yes/No) \rightarrow Eg : Sedation.
- Population response noted.
- In 50% population, dose required to cause :
 - Effect : ED_{50} (marker of potency).
 - Toxicity : TD_{50}
 - Lethality : LD_{50} $\left. \begin{array}{l} \text{Toxicity} \\ \text{Lethality} \end{array} \right\} \text{marker of toxicity.}$

Note : Lethality checked only in animals.